The role of growth factors in central nervous system tumours

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1681-1686

  Nieder, Carsten ^a   Schlegel, Juergen ^a   Andratschke, Nicolaus ^b   Thamm, Reinhard ^a   Grosu, Anca L ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brain tumours; Glioblastoma multiforme; Glioma; Growth factors; Meningioma; Prognostic factors; Radiotherapy

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GROWTH FACTOR; IMATINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCATTER FACTOR; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DNA SYNTHESIS; EPENDYMOMA; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOREACTIVITY; MALIGNANT MENINGIOMA; MEDULLOBLASTOMA; MENINGIOMA; NEURILEMOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR RECURRENCE; VASCULARIZATION;

ANIMALS; CELL DIVISION; CENTRAL NERVOUS SYSTEM NEOPLASMS; GROWTH SUBSTANCES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0038200666     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Louis DN: Clinicopathogenetic subsets of glioblastoma multiforme: from both sides now [Editorial]. Brain Pathol 6: 223-224, 1996.
2. Hiesiger EM, Hayes RL, Pierz DM et al: Prognostic relevance of epidermal growth factor receptor and c-neu/erbB2 expression in glioblastomas. J Neurooncol 16: 93-104, 1993.
3. Schlegel J, Merdes A, Stumm G et al: Amplification of the epidermal growth factor receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77, 1994.
4. Zhu A, Shaeffer J, Leslie S et al: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 34: 809-815, 1996.
5. Smith JS, Tachibana I, Passe SM et al: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001.
6. nd, Simmons ML, Chang SM et al: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51: 410-418, 2001.
7. Chakravarti A, Delaney MA, Noll E et al: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7: 2387-2395, 2001.
8. Muracciole X, Romain S, Dufour H et al: PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 52: 592-598, 2002.
9. Simmons ML, Lamborn KR, Takahashi M et al: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61: 1122-1128, 2001.
10. Lammering G, Valerie K, Lin PS et al: Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 7: 682-690, 2001.
11. Jennings MT and Pietenpol JA: The role of transforming growth factor b in glioma progression. J Neurooncol 36: 123-140, 1998.
12. Dhandapani KM, Wade MF, Mahesh VB et al: Basic fibroblast growth factor induces TGF-beta release in an isoform and glioma-specific manner. Neuroreport 13: 239-241, 2002.
13. Wick W, Platten M and Weller M: Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53: 177-185, 2001.
14. Fakhrai H, Dorigo O, Shawler DL et al: Eradication of established intracranial rat gliomas by transforming growth factor b antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914, 1996.
15. Hulshof MC, Sminia P, Barten-van Rijbroek AD et al: Prognostic value of plasma transforming growth factor-beta in patients with glioblastoma multiforme. Oncol Rep 8: 1107-1110, 2001.
16. Trojan J, Johnson TR, Rudin SD et al: Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor-1 RNA. Science 259: 94-97, 1993.
17. Andrews DW, Resnicoff M, Flanders AE et al: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19: 2189-2200, 2001.
18. Bogler O, Huang HJ, Kleihues P et al: The p53 gene and its role in human brain tumors. Glia 15: 308-327, 1995.
19. Morrison RS: Growth factor-mediated signaling pathways. In: The Gliomas (Berger MS and Wilson CB, eds). Philadelphia, W.B. Saunders, 1999, pp 52-63.
20. Wen PY, Yung WK, Hess K et al: Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99-08, Abstract 288). Proc Am Soc Clin Oncol 21: 73a, 2002.
21. Fukumura D, Xu L, Chen Y et al: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumours in vivo. Cancer Res 61: 6020-6024, 2001.
22. Bjerkvig R, Lund-Johansen M and Edvardsen K: Tumor cell invasion and angiogenesis in the central nervous system. Curr Opin Oncol 9: 223-229, 1997.
23. van der Valk P, Lindeman J and Kamphorst W: Growth factor profiles of human gliomas. Ann Oncol 8: 1023-1029, 1997.
24. Plate K and Risau W: Angiogenesis in malignant glioma. Glia 15: 339-347, 1995.
25. Kim KJ, Li B, Winer J et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
26. Lee CG, Heijn M, di Tomaso E et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570, 2000.
27. Geng L, Donnelly E, McMahon G et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61: 2413-2419, 2001.
28. Yung WA, Friedman H, Jackson E et al: A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma (Abstract 315). Proc Am Soc Clin Oncol 21: 79a, 2002.
29. Auguste P, Gursel DB, Lemiere S et al: Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 61: 1717-1726, 2001.
30. Smith JS, Wang XY, Qian J et al: Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 59: 495-503, 2000.
31. Guha A, Dashner K, Black PM et al: Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60: 168-173, 1995.
32. Mauro A, Bulfone A, Turco E et al: Coexpression of platelet-derived growth factor (PDGF) B chain and PDGF B-type receptor in human gliomas. Childs Nerv Syst 7: 432-436, 1991.
33. Nishikawa R, Cheng SY, Nagashima R et al: Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 96: 453-462, 1998.
34. Oehring RD, Miletic M, Valter MM et al: Vascular endothelial growth factor in astrocytic gliomas - a prognostic factor? J Neurooncol 45: 117-125, 1999.
35. Korshunov A and Golanov A: The prognostic significance of vascular endothelial growth factor immunoexpression in oligodendroglioma. J Neurooncol 48: 13-9, 2000.
36. Pietsch T, Valter MM, Wolf HK et al: Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 93: 109-117, 1997.
37. Abdulrauf SI, Edvardsen K, Ho KL et al: Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88: 513-520, 1998.
38. Friend KE, Khandwala HM, Flyvbjerg A et al: Growth hormone and insulin-like growth factor-1: effects on the growth of glioma cell lines. Growth Horm IGF Res 11: 84-91, 2001.
39. Hirano H, Lopes MB, Laws ER et al: Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro-oncol 1: 109-119, 1999.
40. Hall WA, Merrill MJ, Walbridge S et al: Epidermal growth factor receptors on ependymomas and other brain tumors. J Neurosurg 72: 641-646, 1990.
41. Herzog C and Schlegel J: EGF-receptor-mediated signaling pathways in human ependymomas (Abstract). Acta Neuropathol 102: 527, 2001.
42. Black P, Carroll RS and Glowacka D: Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas. Pediatr Neurosurg 24: 74-78, 1996.
43. Nagashima G, Aoyagi M, Yamamoto S et al: Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningeomas. Clin Neurol Neurosurg 103: 13-18, 2001.
44. Yang SY and Xu GM: Expression of PDGF and its receptors as well as their relationship to proliferating activity and apoptosis of meningeomas in human meningeomas. J Clin Neurosci 8 Suppl 1: 49-53, 2001.
45. Black PM, Carroll R, Glowacka D et al: Platelet-derived growth factor expression and stimulation in human meningeomas. J Neurosurg 81: 388-393, 1994.
46. Christov C, Lechapt-Zalcman E, Adle-Biassette H et al: Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas Acta Neuropathol (Berl) 98: 414-420, 1999.
47. Lamszus K, Lengler U, Schmidt NO et al: Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human menigeomas and their relation to angiogenesis and malignancy. Neurosurgery 46: 938-947, 2000.
48. Schlegel J, Ullrich B, Stumm G et al: Expression of the c-erbB-2 encoded oncoprotein and progesterone receptor in human meningioma. Acta Neuropathol 86: 474-479, 1993.
49. Leon SP, Carroll RS, Dashner K et al: Messenger ribonucleic acid expression of platelet-derived growth factor subunits and receptors in pituitary adenomas. J Clin Endocrinol Metabol 79: 51-55, 1994.
50. Smits A, van Grieken D, Hartman M et al: Coexpression of platelet-derived growth factor alpha and beta receptors on medulloblastomas and other primitive neuroectodermal tumors is consistent with an immature stem cell and neuronal derivation. Lab Invest 74: 188-198, 1996.
51. Duplan SM, Theoret Y and Kenigsberg RL: Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 8: 246-257, 2002.
52. Weerda HG, Gamberger TI, Siegner A et al: Effects of transforming growth factor-beta1 and basic fibroblast growth factor on proliferation of cell cultures derived from human vestibular nerve schwannoma. Acta Otolaryngol 118: 337-343, 1998.
53. Nikitin AY, Ballering LA, Lyons J et al: Early mutation of the neu (erb-B2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage. Proc Natl Acad Sci USA 88: 9939-9943, 1991.
54. Schlegel J, Muenkel K, Trenkle T et al: Expression of the ERBB2/neu and Neurofibromatosis type 1 gene products in reactive and neoplastic Schwann cell proliferation. Int J Oncol 13: 1281-1284, 1998.
55. Kirsch M, Wilson JC and Black P: Platelet-derived growth factor in human brain tumors. J Neurooncol 35: 289-301, 1997.
56. Nieder C, Ataman F, Price RE et al: Radiation myelopathy: new perspective on an old problem. Radiat Oncol Invest 7: 193-203, 1999.
57. Nieder C, Price RE, Rivera B et al: Experimental data for insulin-like growth factor-1 and basic fibroblast growth factor in prevention of radiation myelopathy [German]. Strahlenther Onkol 178: 147-152, 2002.
58. Ding I, Huang K, Snyder ML et al: Tumor growth and radiosensitivity in mice given myeloprotective doses of fibroblast growth factors. J Natl Cancer Inst 88: 1399-1404, 1996.
59. Okunieff P, Mester M, Wang J et al: In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat Res 150: 204-211, 1998.
60. Pena LA, Fuks Z and Kolesnick RN: Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 60: 321-327, 2000.
61. Nieder C, Andratschke N, Price RE et al: Innovative prevention strategies for radiation necrosis of the central nervous system. Anticancer Res 22: 1017-1023, 2002.
62. Paris F, Fuks Z, Kang A et al: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297, 2001.
63. Andratschke N, Grosu AL, Molls M et al: Perspectives in the treatment of malignant gliomas in adults. Anticancer Res 21: 3541-3550, 2001.